| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
16,430,000 |
| Market
Cap: |
4.93(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.3 - $0.3 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile NeuroBo Pharmaceuticals is a clinical-stage biotechnology company. ANA001, Co.'s drug candidate, is an oral niclosamide formulation and is being developed as a treatment for patients with moderate coronavirus disease (patients not requiring ventilators). Co.'s NB-01 addresses various mechanisms that contribute to neuropathic pain and nerve degeneration in diabetic and other peripheral neuropathies. Co.'s NB-02 is in development for the symptomatic and disease modifying treatment of neurodegenerative diseases, including Alzheimer's disease and tauopathies. Co.'s Gemcabene is an oral therapy designed to target known lipid metabolic pathways to lower levels of LDL-C, hsCRP and triglycerides.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Sooch Mina |
President & CEO |
• • – |
2016-08-10 |
4 |
B |
$10.00 |
$525,000 |
D/D |
52,500 |
693,732 |
2.81 |
- |
|
| Sooch Mina |
President & CEO |
• • – |
2016-08-10 |
4 |
A |
$0.00 |
$182,005 |
I/I |
38,219 |
39,431 |
|
- |
|
| Sooch Mina |
President & CEO |
• • – |
2016-08-10 |
4 |
A |
$6.71 |
$8,128 |
I/I |
1,212 |
12,290 |
|
- |
|
| Oniciu Carmen Daniela |
Vice President |
• – – |
2016-08-10 |
4 |
A |
$6.71 |
$1,643 |
D/D |
245 |
152,401 |
|
- |
|
| Oniciu Carmen Daniela |
Vice President |
• – – |
2016-08-10 |
4 |
A |
$0.00 |
$0 |
D/D |
2,237 |
152,156 |
|
- |
|
| Lowenschuss David |
Chief Legal Off. & Secretary |
• – – |
2016-08-10 |
4 |
B |
$10.00 |
$111,200 |
D/D |
11,120 |
806,247 |
2.74 |
- |
|
| Mathiesen Jeffrey S |
Chief Financial Officer |
• – – |
2016-08-10 |
4 |
B |
$10.00 |
$40,000 |
D/D |
4,000 |
7,927 |
2.74 |
- |
|
| Mathiesen Jeffrey S |
Chief Financial Officer |
• – – |
2016-08-10 |
4 |
OE |
$6.71 |
$26,334 |
D/D |
3,927 |
3,927 |
|
- |
|
| Bisgaier Charles Phd |
Chair & Chief Scientific Off. |
• • • |
2016-08-10 |
4 |
B |
$10.00 |
$517,500 |
D/D |
51,750 |
1,244,440 |
3.23 |
- |
|
| Bisgaier Charles Phd |
Chair & Chief Scientific Off. |
• • • |
2016-08-10 |
4 |
A |
$0.00 |
$237,201 |
I/I |
94,933 |
19,228 |
|
- |
|
| Bisgaier Charles Phd |
Chair & Chief Scientific Off. |
• • • |
2016-08-10 |
4 |
A |
$6.71 |
$43,689 |
I/I |
6,515 |
66,076 |
|
- |
|
| Bisgaier Charles Phd |
Chair & Chief Scientific Off.O |
• • • |
2016-08-04 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,192,690 |
|
- |
|
| Sooch Mina |
President, CEO & TreasurerOffi |
• • • |
2016-08-04 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
641,232 |
|
- |
|
| Lowenschuss David |
Chief Legal Off. & SecretaryOf |
• – • |
2016-08-04 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
795,127 |
|
- |
|
| Hawryluk P. Kent |
Director |
– • – |
2016-08-04 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
32,062 |
|
- |
|
| Oniciu Carmen Daniela |
VP of PreClinical R&D & Manf.O |
• – – |
2016-08-04 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
149,919 |
|
- |
|
66 Records found
|
|
Page 3 of 3 |
|
|
